全身评分可识别Still病危及生命的演变:来自GIRRCS AOSD研究组与AIDA网络Still病登记处的数据
多中心、观察性、前瞻性研究纳入597例Still病患者,评估全身评分对危及生命演变(死亡和/或巨噬细胞活化综合征)的预测价值。全身评分作为连续变量显著预测危及生命演变(OR 1.24;95%CI 1.07-1.42;P=0.004),全身评分≥7同样显著预测(OR 3.36;95%CI 1.81-6.25;P<0.001)。肝脏受累(OR 1.68;95%CI 1.48-2.67;P=0.031)和肺部疾病(OR 2.12;95%CI 1.14-4.49;P=0.042)均显著预测危及生命演变。
要点
- 全身评分作为连续变量显著预测Still病危及生命演变(OR 1.24;95%CI 1.07-1.42;P=0.004)。
- 全身评分≥7显著预测危及生命演变(OR 3.36;95%CI 1.81-6.25;P<0.001)。
- 肝脏受累和肺部疾病均显著预测危及生命演变,并突出其在多器官病变中的意义。
核心结论
- 全身评分在大型队列中显示出识别Still病危及生命演变较高风险的临床效用,并突出了肝脏受累和肺部疾病的临床相关性。
研究设计与样本
- 多中心、观察性、前瞻性研究,纳入意大利临床风湿病学研究组成人Still病研究组与自身炎症疾病联盟网络Still病登记处的597例Still病患者(平均±标准差年龄36.6±17.3岁;男性44.4%)。
主要发现
- 全身评分作为连续变量显著预测危及生命演变(OR 1.24;95%CI 1.07-1.42;P=0.004)。
- 全身评分≥7显著预测患者发生危及生命演变的可能性(OR 3.36;95%CI 1.81-6.25;P<0.001)。
- 肝脏受累显著预测危及生命演变(OR 1.68;95%CI 1.48-2.67;P=0.031)。
- 肺部疾病显著预测危及生命演变(OR 2.12;95%CI 1.14-4.49;P=0.042)。
- 研究推导了肝脏受累和肺部疾病患者的临床特征,突出其在多器官疾病表现中的相关性。
关键数值与推荐
- 危及生命演变定义为死亡(无论临床病程如何)和/或巨噬细胞活化综合征(一种与不良预后相关的继发性噬血细胞性淋巴组织细胞增多症)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to evaluate the clinical usefulness of the systemic score in the prediction of life-threatening evolution in Still disease. We also aimed to assess the clinical relevance of each component of the systemic score in predicting life-threatening evolution and to derive patient subsets accordingly. METHODS: A multicenter, observational, prospective study was designed including patients included in the Gruppo Italiano Di Ricerca in Reumatologia Clinica e Sperimentale Adult-Onset Still Disease Study Group and the Autoinflammatory Disease Alliance Network Still Disease Registry. Patients were assessed to see if the variables to derive the systemic score were available. The life-threatening evolution was defined as mortality, whatever the clinical course, and/or macrophage activation syndrome, a secondary hemophagocytic lymphohistiocytosis associated with a poor prognosis. RESULTS: A total of 597 patients with Still disease were assessed (mean ± SD age 36.6 ± 17.3 years; male 44.4%). The systemic score, assessed as a continuous variable, significantly predicted the life-threatening evolution (odds ratio [OR] 1.24; 95% confidence interval [CI] 1.07-1.42; P = 0.004). A systemic score ≥7 also significantly predicted the likelihood of a patient experiencing life-threatening evolution (OR 3.36; 95% CI 1.81-6.25; P < 0.001). Assessing the clinical relevance of each component of the systemic score, liver involvement (OR 1.68; 95% CI 1.48-2.67; P = 0.031) and lung disease (OR 2.12; 95% CI 1.14-4.49; P = 0.042) both significantly predicted life-threatening evolution. The clinical characteristics of patients with liver involvement and lung disease were derived, highlighting their relevance in multiorgan disease manifestations. CONCLUSION: The clinical utility of the systemic score was shown in identifying Still disease at a higher risk of life-threatening evolution in a large cohort. Furthermore, the clinical relevance of liver involvement and lung disease was highlighted.
引用
- Ruscitti P, Masedu F, Vitale A, et al. The Systemic Score May Identify Life-Threatening Evolution in Still Disease: Data from the GIRRCS AOSD-Study Group and the AIDA Network Still Disease Registry. Arthritis Rheumatol. 2024. PMID: 38499989. doi:10.1002/art.42845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。